Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin consolidation after first-line R-CVP in PET-positive partial remission follicular lymphoma
2009-012944-17Phase 2Active
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jun 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL) and mature B-cell lymphoma, sponsored by Vanderbilt University Medical Center. Primary endpoint: Conversion rate from partial remission to complete remission. Started Jun 2009; status: active.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2009-012944-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012944-17.